Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYRE vs MDGL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYRE Captures Overall Composite Edge (36.1 SELL vs 54.0 HOLD), While MDGL Leads 4–1 on Growth & Valuation Pillars

SYRE Overall Winner 6-Pillar Tally: SYRE 1 – 4 MDGL (1 Tie) Matrix Metrics: SYRE 3 – 7 MDGL

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Madrigal Pharmaceuticals, Inc. (MDGL) on higher Unified Composite conviction (36.1/100 SELL vs. 54.0/100 HOLD) after splitting the core matrix 3–7 (led by Profitability & Quality), while MDGL wins 4–1 across the 6-pillar growth and valuation breakdown. SYRE trades at $99.97 (N/M Forward P/E, 0.0% operating margin) versus MDGL at $423.54 (38.1x Forward P/E, -10.7% operating margin).

  • Composite vs. Pillar Nuance: While MDGL currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (3–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.7% operating margin) and revenue trajectory (+0.0% vs. +50.1% YoY).
  • Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile MDGL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYRE vs MDGL
SYRE NASDAQ Head-to-Head Winner
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.6 · SMA20: $98.90 · SMA50: $91.75
MDGL NASDAQ
Madrigal Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$423.54
-0.9% 1D
Market Cap $9.8B
TTM Revenue $1.43B
Forward P/E 38.1x
Beta / 30D Vol 0.28β · 49% Vol
Unified Composite Score
54.0 / 100 HOLD
Tech 73.0 Fund 56.0 Flow 63.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.7%), weak momentum, RSI 42
RSI-14: 42.0 · SMA20: $429.46 · SMA50: $473.43

6-Pillar Scorecard Institutional Category Breakdown (SYRE 1 – 4 MDGL)

Columns: Metric · SYRE · MDGL
1. Valuation Multiples MDGL
Forward P/E N/M 38.1x
Trailing P/E N/M 61.4x
PEG Ratio N/M N/M
EV / Revenue N/M 6.8x
2. Growth & Scale MDGL
Revenue Growth (YoY) +0.0% +50.1%
Earnings Growth (YoY) -99.7% +0.0%
TTM Revenue (USD) N/A $1.43B
Market Cap $9.8B $9.8B
3. Profitability & Quality SYRE
Gross Margin N/A 91.0%
Operating Margin 0.0% -10.7%
Net Profit Margin 0.0% -10.9%
Return on Equity (ROE) -35.0% -24.8%
4. Balance Sheet & Cash Flow MDGL
Cash Generation (TTM) N/A -$169M
Cash Flow Margin N/A -11.8%
Net Cash / Leverage $10.06 Book/Sh · -35.0% ROE $160M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MDGL
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 87.9% (10th %ile) 59.0% (13th %ile)
Put/Call OI Skew N/A 0.28x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYRE (3) vs MDGL (7)
Institutional Metric SYRE MDGL Criterion Row Edge
Market Capitalization
Scale
$9.8B $9.8B Larger Scale MDGL
Trailing P/E Ratio
Valuation
N/M 61.4x Lower Multiple MDGL
Forward P/E Ratio
Valuation
N/M 38.1x Lower Multiple MDGL
Revenue Growth (YoY)
Growth
+0.0% +50.1% Higher Growth MDGL
Operating Margin (TTM)
Profitability
0.0% -10.7% Higher Margin SYRE
Net Profit Margin
Profitability
0.0% -10.9% Higher Margin SYRE
Return on Equity (ROE)
Capital Efficiency
-35.0% -24.8% Higher ROE MDGL
52-Week Range Position
Momentum
88% ($22–$111) 27% ($354–$615) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.75β · 59% Vol 0.28β · 49% Vol Lower Realized Risk MDGL
Unified Institutional Score
Composite Signal
36.1 / 100 (SELL) 54.0 / 100 (HOLD) Higher Composite MDGL
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.43B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 91.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.06 Book/Sh · -35.0% ROE) -$169M ($160M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +30.94 pp
SYRE: +25.11% · MDGL: -5.83%
3M Horizon SYRE +11.94 pp
SYRE: -7.29% · MDGL: -19.23%
6M Horizon SYRE +61.54 pp
SYRE: +42.64% · MDGL: -18.9%
1Y Horizon SYRE +359.49 pp
SYRE: +341.74% · MDGL: -17.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs MDGL. Trailing 12-month operating profitability (SYRE 0.0% vs MDGL -10.7%) and valuation multiples (SYRE N/M vs MDGL 38.1x Forward P/E) are benchmarked directly in Pillar 4 below.

SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M
MDGL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.43B
Gross Margin91.0%
Op. Margin-10.7%
ROE / Fwd P/E-24.8% · 38.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MDGL CONSOLIDATION
157d in phase · OBV DISTRIBUTION
Current IV 59.0%
IV Percentile 13th %ile
Put/Call OI Skew 0.28x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MDGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MDGL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and -10.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SYRE vs MDGL Key Questions & Quantitative Answers

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Madrigal Pharmaceuticals, Inc. (MDGL) on higher Unified Composite conviction (36.1/100 SELL vs. 54.0/100 HOLD) after splitting the core matrix 3–7 (led by Profitability & Quality), while MDGL wins 4–1 across the 6-pillar growth and valuation breakdown. SYRE trades at $99.97 (N/M Forward P/E, 0.0% operating margin) versus MDGL at $423.54 (38.1x Forward P/E, -10.7% operating margin). Composite vs. Pillar Nuance: While MDGL currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (3–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.7% operating margin) and revenue trajectory (+0.0% vs. +50.1% YoY). Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile MDGL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MDGL leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MDGL at +50.1% YoY revenue growth and +0.0% YoY earnings growth on $1.43B TTM revenue (91.0% gross margin, -10.7% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $1.43B for MDGL. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MDGL.

MDGL screens cheaper on headline valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MDGL trades at 38.1x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-11.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus MDGL (-24.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, MDGL carries 59.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 0.28x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.